Realized is reliable fixation of a material in a fluid state containing a monovalent metal salt of alginic acid when the material is applied to a subject. A combination of compositions comprising a first material composition containing a monovalent metal salt of alginic acid and a second material composition containing a cross-linking agent having an action of cross-linking the monovalent metal salt of alginic acid, wherein the combination is to be used in such a way as to apply the first material composition to a subject in a fluid state and contact the second material composition with the first material composition applied to the subject to gel at least a part of the first material composition, wherein the first material composition further contains a coloring component so that a formation state of a gel coat on a surface of the first material composition applied to the subject can be evaluated.

Realized is reliable fixation of a material in a fluid state containing a monovalent metal salt of alginic acid when the material is applied to a subject. A combination of compositions comprising a first material composition containing a monovalent metal salt of alginic acid and a second material composition containing a cross-linking agent having an action of cross-linking the monovalent metal salt of alginic acid, wherein the combination is to be used in such a way as to apply the first material composition to a subject in a fluid state and contact the second material composition with the first material composition applied to the subject to gel at least a part of the first material composition, wherein the first material composition further contains a coloring component so that a formation state of a gel coat on a surface of the first material composition applied to the subject can be evaluated.

The present invention relates to a composition comprising 4-hexylresorcinol(4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

The present invention relates to a composition comprising 4-hexylresorcinol(4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

The invention provides the use of mesenchymal stem cells for preparing drugs/medicines for the treatment of non-healing burn wounds. The inventor found that the mesenchymal stem cells of the present application are used to treat burn wounds and have significant curative effects. They can effectively promote the repair of hard-to-heal burn wounds, increase the healing rate of hard-to-heal burn wounds, and shorten wound healing time, with non-toxic side effects, easy absorption and other advantages. Therefore, the mesenchymal stem cells and the composition containing them can be used to prepare drugs/medicines for treating non-healing burn wounds.

The invention provides the use of mesenchymal stem cells for preparing drugs/medicines for the treatment of non-healing burn wounds. The inventor found that the mesenchymal stem cells of the present application are used to treat burn wounds and have significant curative effects. They can effectively promote the repair of hard-to-heal burn wounds, increase the healing rate of hard-to-heal burn wounds, and shorten wound healing time, with non-toxic side effects, easy absorption and other advantages. Therefore, the mesenchymal stem cells and the composition containing them can be used to prepare drugs/medicines for treating non-healing burn wounds.

Provided are a composition for treating or preventing recurrence of keloid comprising tauroursodeoxycholic acid as an active ingredient, and a method for treating keloid or preventing recurrence of keloid using the composition.

Provided are a composition for treating or preventing recurrence of keloid comprising tauroursodeoxycholic acid as an active ingredient, and a method for treating keloid or preventing recurrence of keloid using the composition.

A composition and method directed to the treatment of bacterial infections is provided.

A composition and method directed to the treatment of bacterial infections is provided.